A recent multiple-centre study reported that pSS patients in China had higher positive rates of anti-nuclear antibody (ANA) and anti-Sjögren’s syndrome-related antigen A (anti-SSA) antibodies than those of patients in Europe and America, indicating that disease heterogeneity among pSS patients in different regions (4). This evidence concerns the gene BTG3 and peeling skin syndrome.